RxSight Exceeds 2025 Revenue Expectations and Appoints New CFO

2026-01-11 companies

Aliso Viejo, Sunday, 11 January 2026.
RxSight surpassed fiscal 2025 revenue guidance with $134.5 million and appointed Mark Wilterding as CFO. Notably, the company has secured a 10% share of the premium intraocular lens market.

Financial Performance Exceeds Forecasts

RxSight, Inc. (Nasdaq: RXST) reported preliminary unaudited revenue of approximately $32.6 million for the fourth quarter of 2025, surpassing the IBES estimate of $28.6 million [1][8]. For the full fiscal year ending December 31, 2025, the company anticipates revenue to reach $134.5 million [1]. This figure exceeds the upper bound of the company’s November guidance range, which had been set at $125 million to $130 million [2][5]. This represents a performance beat of approximately 3.462 percent over the high end of their previous forecast.

Operational Growth and Market Penetration

The revenue acceleration was driven by strong procedural volumes across the company’s product lines. In the fourth quarter alone, RxSight sold 28,611 Light Adjustable Lenses (LAL), marking a 10% increase in procedure volume compared to the third quarter of 2025 [2][5]. On an annual basis, LAL sales totaled 109,615 units, representing a 12% increase over the figures recorded in 2024 [4][5]. The company also expanded its infrastructure, selling 25 Light Delivery Devices (LDD) in the fourth quarter to bring the total installed base to 1,134 units [1][5].

Strategic Leadership Transition

Coinciding with the financial update, RxSight announced the appointment of Mark Wilterding as the new Chief Financial Officer, effective January 11, 2026 [1][5]. Wilterding brings over 25 years of financial leadership experience to the role, having most recently served as Senior Vice President of Global Finance at Edwards Lifesciences since 2019 [5]. His background also includes tenure at Medtronic and 15 years in the banking sector with Citi and Credit Suisse [5]. Wilterding succeeds Shelley Thunen, who entered into a transition agreement on January 10, 2026, and will continue to assist the company in a consulting capacity [2][5].

Analyst Sentiment and Future Outlook

Following the preliminary announcement on January 10, 2026, financial analysts adjusted their outlooks for the company. Needham raised its price target for RxSight to $12, while Stifel increased its target from $8 to $10, though it maintained a “Hold” rating [2]. As of January 8, 2026, the stock was trading at $9.57, reflecting a market capitalization of approximately $393.49 million [7]. RxSight plans to release its full audited financial results for 2025 and provide guidance for 2026 in February 2026 [1][3].

Sources

Medical Devices Executive Leadership